Journal article
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
Abstract
New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately 10% of tumors show primary resistance, whereas acquired resistance appears to be an almost ubiquitous occurrence, leading to treatment failure. The …
Authors
Krasniqi E; Goeman F; Pulito C; Palcau AC; Ciuffreda L; Di Lisa FS; Filomeno L; Barba M; Pizzuti L; Cappuzzo F
Journal
International Journal of Molecular Sciences, Vol. 23, No. 23,
Publisher
MDPI
DOI
10.3390/ijms232314534
ISSN
1661-6596